Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

The Materiality of Superbugs: Investor Action on Antimicrobial Resistance

On 23 November, the Access to Medicine Foundation, together with partners, will host this virtual event as a part of World Antimicrobial Awareness Week 2020. 

Date

23 November 2020

Update: You can watch the webinar recording here.

The event is organised by the Investor Action on AMR Initiative and was launched by the Access to Medicine Foundation, the FAIRR Initiative, the UK Department of Health & Social Care, and the Principles for Responsible Investment (PRI) at the World Economic Forum Annual Meeting in Davos in January 2020.

The virtual event will explore the financially material impacts of drug-resistant superbugs and the benefits of action to address them. The event will also introduce the first Investor Partners to the initiative, discuss upcoming activities and, importantly, why investors and financial institutions should join and how.

The keynote speech will be delivered by Professor Dame Sally Davies – UK Special Envoy on Antimicrobial Resistance & former Chief Medical Officer for England. The panel discussion will be moderated by Fiona Reynolds, CEO, PRI.

The webinar will take place on Monday, 23 November at 6-7pm CET / 5-6pm GMT / 12-1pm ET. You can register for the webinar here.

About the Investor Action on AMR Initiative

On 23rd January 2020 at the World Economic Forum Annual Meeting in Davos, the Access to Medicine Foundation, FAIRR, PRI and the UK Government launched a new initiative – Investor Action on Antimicrobial Resistance – focused on tackling the global threat of drug-resistant infections.

The main objective of the Investor Action on AMR initiative is to leverage investor influence to combat drug-resistant superbugs – an urgent public health challenge that is responsible for at least 700,000 deaths globally each year and set to rise to 10 million a year by 2050, costing the world $100 trillion USD in global economic losses.    

Please contact Mara Lilley at mlilley@accesstomedicinefoundation.org for more information about how you can join the initiative.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved